Purpose: Despite the advances in the pharmacological treatment of epilepsy, pharmacoresistance still remains challenging. Understanding of the pharmacogenetic causes is critical to predict drug response hence providing a basis for personalized medications. Genetic alteration in activity of drug target and drug metabolizing proteins could explain the development of pharmacoresistant epilepsy. So the aim of this study was to explore whether SCN1A c.3184 A/G (rs2298771) and CYP3A5*3 (rs776746) polymorphisms could serve as genetic based biomarkers to predict pharmacoresistance among Egyptian epileptic children. Methods: Genotyping of SCN1A c.3184 A/G and CYP3A5*3 polymorphisms using the polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) method was performed in 65 healthy control subjects and 130 patients with epilepsy, of whom 50 were drug resistant and 80 were drug responsive.
Introduction
Epilepsy is a debilitating life-long neurological disorder. Despite advances in the therapeutic options, about one third of patients still remain pharmacoresistant [1] . The concept of pharmacoresistance extends beyond being a side effect of treatment to represent a huge burden to patients and societies [2] . The fact that patient's genotype affect its phenotype, suggests that variations in drug response could be explained, at least in part, by personal genetic variations [3] . Polymorphic genes encoding drug targets (SCN1A c.3184 A/G) and drug-metabolizing enzymes (CYP3A5*3) could be utilized to predict antiepileptic drugs (AEDs) outcome [4] .
SCN1A gene encodes the alpha subunit of voltage gated sodium channel type 1 that initiates firing of brain neurons [5, 6] . These ion channels are molecular targets for many AEDs [7] which block ionic conductance through these channels [4, 8] . The architecture of these channels reveals a large pore-forming a subunit associated with two smaller b subunits [5, 9] and evidence suggests that the channel blocking AEDs do so mainly by binding a subunit [8] . Previous studies documented most of de novo mutations in the sodium-channel gene SCN1A cause severe myoclonic epilepsy of infancy, also the association of SCN1A mutations with familial epilepsy [10] [11] [12] [13] and moreover with drug effectiveness [12, [14] [15] [16] . The protein coding missense c.3184 A/G polymorphism of SCN1A results in p.Thr1067Ala change [17] . This polymorphism could affect the concerted gating of these channels by altering their structure-function relationship rendering them insensitive to the blocking effect of AEDs so that the question of why some patients respond to AEDs while others do not might be answered by this polymorphism [12] .
Another issue that could be incriminated in pharmacoresistant epilepsy is drug metabolism. AEDs are primarily metabolized by phase I oxidative CYP3A subfamily [18] [19] [20] [21] . Being the chief members, CYP3A4 and CYP3A5 account for the CYP3A activity [3, [22] [23] [24] . In contrast to CYP3A4,CYP3A5 gene is highly polymorphic with interindividual variability in expression and catalytic activity [3, 10, 23, 25, 26] resulting in variable metabolism of its substrates [27, 28] , so CYP3A5 genetic polymorphism could modulate response to AEDs [3] . This variability could be attributed to the functional variant CYP3A5*3 (rs776746) in intron 3 resulting in splicing defect and truncated CYP3A5 protein of no catalytic activity [29] [30] [31] [32] [33] [34] .
Thus in this study we genotyped the SCN1A c.3184 A/G and CYP3A5*3 polymorphisms in Egyptian epileptic patients either drug sensitive or drug resistant, to evaluate the association of these polymorphisms with epilepsy and their role in resistance to AEDs.
Patients and methods

Patients and setting
This study included 130 Egyptian epileptic children treated with AEDs, 80 patients are drug responders (55 males and 25 females) with mean age of 8.34 AE 2.95 years and 50 patients are drug resistant (25 males and 25 females) with mean age of 7.43 AE 2.95. All epileptic children were recruited from the Pediatrics Department, Menoufia University Hospital, Egypt. The subjects were seen over a period of 6 months in the pediatric neurology clinic sequentially until the study was filled. The patients were considered to be drug responsive if they had not experienced any type of seizures for a minimum of 1 year after receiving AEDs. Drug-resistant epilepsy was defined as uncontrolled seizures over a year, despite attempts to treat with three or more different AEDs. The antiseizure medications were chosen according to the type of seizures and epilepsy syndrome. Polypharmacy was determined by numbers of medication ever used, not only at enrollment into the study. Any patients suspected of poor compliance or with known SCN1A mutations were excluded from the study. Clinical data and medical history of each patient were also collected. The controls consisted of 65 age and gender matched healthy children (36 males and 29 females) with mean age of 7.48 AE 2.50 with negative individual and family history, as regards epilepsy and febrile convulsions. The controls were recruited from outpatient general pediatric clinic after being treated for simple infections, as common cold. All patients and/or their parents gave their written consent to participate in the study. The protocol was approved by the Menoufia University Ethics Committees.
DNA analysis
Genomic DNA was extracted from EDTA-anticoagulated peripheral blood (QIAamp DNA Blood Mini Kit, QIAGEN).
2.2.1. Genotyping of SCN1A c.3184 A/G polymorphism [10] Fragments containing polymorphic sites were amplified with the following forward and reverse primers {F: 5 0 -TGCACAAAG-GAGTAGCTTATG-3 0 and R: 5 0 -AGTCAAGATCTTTCCCAATTTCAG-3 0 } by PCR in a final volume of 25 mL containing 10 mL genomic DNA, 12.5 mL DreamTag green PCR master mix (Thermo Scientific), 1 mL of each primer and 0.5 mL of DNase/RNase free water. PCR conditions were as follows: a denaturing step at 95 C for 5 min, then 40 cycles at 94 C for 30 s, 57 C for 1 min, 72 C for 1 min, and a final incubation at 72 C for 7 min. After amplification, The SCN1A c.3184 A/G polymorphism was identified by PvuII restriction enzyme (A allele; 168 bp, G allele; 145 and 23 bp separated in 2% agarose gel containing ethidium bromide).
Genotyping of CYP3A5*3 polymorphism [26]
The genomic DNA was amplified with the use of specific forward and reverse primers {F: 5 0 -CTTTTAAGAGCTCTTTTGTCTCTC A-3 0 and R: 5 0 -CCAGGAAGCCAGACTTTGAT-3 0 }. The 25 mL PCR mixture for reaction contained 10 mL genomic DNA, 12.5 mL DreamTag green PCR master mix (Thermo Scientific), 1 mL of each primer and 0.5 mL of DNase/RNase free water. After denaturation at
94
C for 5 min, the amplification was carried out for 40 cycles at 94 C for 30 s, at 56 C for 1 min, and at 72 C for 1 min. The terminal elongation was carried out at 72 C for 7 min. After amplification the PCR product (200 bp) was cleaved by the restriction enzyme DdeI (Fermentas), obtaining fragments of 129, 107, 71, and 22 bp for allele *1, as well as 107, 71, and 22 bp for allele *3. The amplified fragments of DNA were separated in 2% agarose gel containing ethidium bromide.
Statistical analysis
Results were collected, tabulated, statistically analyzed by statistical package SPSS version 20 (SPSS Chicago., Inc.). MannWhitney test and Kruskal-Wallis test were used for nonparametric variables. Chi-Squared (x 2 ) and Fisher's exact test were used for qualitative variables. p value 0.05 was considered significant.
Results
Out of the 130 children with epilepsy, drug-resistant epilepsy was diagnosed in 50 children and drug-responsive epilepsy in 80 children. The mean age of the drug-resistant patients was 7.43 AE 2.95 years vs. drug responders, in whom it was 8.34 AE 2.95 years (Table 1) . Among the 130 epileptic children epilepsy was more frequent in male in comparison to female (61.5% vs.38.5% respectively). Mean age of onset for seizures in drug-resistant was (Table 2) . Mean duration of epilepsy and seizure frequency showed highly statistically significant difference between the two epileptic patient groups (p = 0.008 and <0.001 respectively) ( Table 2 ). There was no statistically significant difference between the two patient groups regarding age of onset for seizures, etiology, seizure pattern and status epilepticus history (Table 2) . According to etiology, idiopathic epilepsy was found in 53.8% of all epileptic patients, while symptomatic and probable symptomatic epilepsies were found in 40% and 6.2% respectively. According to seizure pattern, the prevalence of generalized epilepsy, focal epilepsy and specific epileptic syndromes were 66.1%, 16.2% and 17.7% respectively. Regarding SCN1A c.3184 A/G polymorphism, there was significantly higher frequency of AG genotype {p = 0.001; OR = 2.97(1.48-5.95)} and G allele {p = 0.006; OR = 1.94(1.19-3.15)} in epileptic patients when compared to that in controls (Table 3) . Also the frequency of the AG genotype {p = 0.005; OR = 3.03(1.36-6.74)} and G allele {p = 0.054; OR = 1.66(0.99-2.79)} were significantly higher in AED-resistant epilepsy than that in AED-responsive epilepsy (Table 4) . To evaluate the effect of SCN1A genotypes on the clinical epileptic characteristics, the epileptic patients were divided into AA carriers and AG + GG carriers ( Table 5) . Comparison of AA carriers group to AG + GG carriers group revealed significantly increased prevalence of the polytherapy phenotype among the mutant genotype group (AG + GG carriers) {p < 0.001}, while comparison of the genotype groups showed no significant association with other clinical parameters (Table 5) .
Regarding CYP3A5*3 gene polymorphism, the most frequently occurring genotype was the CYP3A5*3/*3 genotype which accounted for 64.0% in drug resistant patients, 50.0% in drug responsive patients and 58.5% in controls. The CYP3A5*1/*1 genotype was the least frequent in the study groups accounted (Tables 3 and 4) . Our results revealed no statistical significance in the distribution of CYP3A5 genotypes and alleles on comparing the patients group and control group and also when comparing drug resistant patients to drug responders (Tables 3 and 4 ). In the analysis of polymorphisms and frequency of AEDs, polytherapy seems to be used as a surrogate for drug resistant epilepsy, and while monotherapy was only present in the drug responsive group, polytherapy was present in both. The initial response to antiepileptic drug therapy is highly predictive of longterm outcome as most of drug responsive were on monotherapy while most patients with refractory epilepsy will undergo multiple drug trials, most often without any noteworthy reduction in seizure frequency. A growing consensus agrees that failure of two AEDs places a patient in a category in which it becomes highly unlikely that further AEDs will successfully control the seizures, even when AEDs with different mechanisms of action are used.
Discussion
To date, this is the first study to examine contribution of both genetic variants of SCN1A c.3184 A/G and CYP3A5*3 polymorphisms to the occurrence of pharmacoresistant epilepsy among Egyptian epileptic children.
According to our results, epilepsy was higher frequent in male vs. female epileptic patients (61.5% and 38.9% respectively) and this is quite similar to previous studies [4, 10, 12] .
The drug targets for several AEDs are voltage gated sodium channels [7] in which several susceptible polymorphic loci are linked to some epileptic disorders [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] [45] . The results of this study confirmed the existence of a significant association of AG genotype and G allele of SCN1A c.3184 polymorphism with epilepsy and pharmacoresistant epilepsy. SCN1A encodes the alpha subunit of type 1 voltage gated sodium channel which mediates initiation and propagation of neuronal action potentials [5, 6] . SCN1A is the most commonly mutated gene incriminated in epileptogenesis [46] . SCN1A c.3184 A/G (rs2298771) is a missense protein coding polymorphism that results in p.Thr1067Ala change which may affect structure-function relationship of the channel leading to misfiring of brain neurons explaining its association with epilepsy [4, 10] . Moreover, impaired channel function as a drug target could alter its sensitivity to AEDs affecting efficacy and patient response [12] . Consistent with our results, Zhou et al., in their study to explore the effect of SCN1A rs2298771 genetic polymorphism on carbamazepine efficacy in Chinese patients with partial epilepsy, they found significant lower level of carbamazepine efficacy among carriers of AG and GG genotypes in comparison to that in carriers of AA genotype, meaning that G allele may confer risk to [10] . On the other hand, other studies found no involvement of rs2298771 SCN1A SNP in pharmacoresistant epilepsy [4, 8, 47, 48] . AEDs are metabolized by CYP3A4, CYP3A5 and CYP2C8 enzymes [3, 21] . Hepatic expression of CYP3A5 is polymorphic thus it may be claimed in pharmacoresistance to its substrates [18, 19, 26, 34, 49] . The intronic variant CYP3A5*3 (rs776746) is the mutant allele resulting in lack of CYP3A5 catalytic activity, while CYP3A5*1 allele is the functional copy of the gene and yields full-enzymatically active CYP3A5 [3, 21, [28] [29] [30] .
In this study the frequency of CYP3A5*3 allele among our epileptic patients was 76.9%. This frequency was quite similar to that observed in a study performed by Panomvana et al. on Thai population (69%) [21] . However, this frequency was lower than that in Caucasians (92%) and higher than that recorded for AfricanAmericans (48%) [10, [23] [24] [25] [26] [27] .
The results of our research did not support the association of CYP3A5*3 with pharmacoresistance among epileptic patients as this study had revealed no statistical significance in the distribution of the three genotypes (*1/*1, *1/*3, *3/*3) and allelic distribution when comparing epileptic children with control, and also when comparing drug responders with drug resistant group. Similarly, Emich-Widera et al. reported no statistically significant difference regarding frequency of *1/*3 and *3/ *3 genotypes between patients resistant to AEDs and those sensitive to drugs [3] . The lack of association of CYP3A5*3 and pharmacoresistance may be explained by; (1) in addition to CYP3A5, CYP3A4 and CYP2C8 metabolize AEDs [3, 21] . (2) Moreover, there is a similarity between CYP3A4 and CYP3A5 regarding structure and substrate specificity, so functionally active enzyme may compensate for the reduced activity of another one decreasing the effect of a single polymorphism within one gene [3, 50] , (3) the CYP3A5 is polymorphic, while CYP3A4 is inducible [3, 23, 25, 26] and the induction affects CYP3A activity more than polymorphism does [34] . As the polytherapy phenotype observed in our drug resistant group (100%) might include an inducer of CYP3A, so that confounding the effect of CYP3A5 genotypes on therapy outcome and this is similar to what documented by Seo et al. who found higher carbamazepine (one of the AEDs) clearance in the CYP3A5*3/*3 group and explained this as patients who used carbamazepine concurrently with the potent inducer being also higher in that group [51] . Panomvana et al. demonstrated that beside effect of CYP3A5 variants, the drug-drug interaction that inhibits or induces CYP3A5 enzyme affects carbamazepine clearance [21] .
Conclusion
While CYP3A5*3 variants did not show any contribution to pharmacoresistant epilepsy, the rs2298771 coding SNP of SCN1A gene could be, at least in part, responsible for development of pharmacoresistance among Egyptian epileptic patients. These pharmacogenetic data could assist clinicians in predicting patient drug response phenotype and allow for molecular-based design of genotype specific therapeutics with greater tolerability and efficacy. This is the basis to personalize epilepsy treatment aiming at improving patient quality of life. Further studies are needed to confirm these results and complete our journey through the pharmacogenetic causes of drug resistant epilepsy.
Conflicts of interest statement
The authors declare no financial or other conflicts of interest related to this work.
Author agreement
I have read and have abided by the statement of ethical standards for manuscripts submitted to E-Seizure-the European Journal of epilepsy.
Ethical approval
All procedures performed in the study were in accordance with the ethical standards of the institutional research committee.
